Abstract
This study is aimed at understanding the role of arsenic in Roxarsone in causing fatty livers in mule ducks. One hundred 10-week-old mule ducks were randomly divided into 5 groups. Ducks received 2 weeks of various treatments followed by 2 weeks of withdrawal. The treatments were non-treatment (control), 300 mg/kg Roxarsone inclusion for 2 weeks (1 s t and 2 n d week), Roxarsone inclusion for one week (2 n d week only), restrict feeding, or Roxarsone analogue (3-nitro-4-hydroxyphenyl acid) inclusion. Results showed that feed intake and body weight in the Roxarsone groups and the restrict feeding group decreased significantly during the treatment period. However only the liver and heart weights were significantly decreased (p<0.05) in the restrict feeding group. Fatty acid synthetase (FAS) activity showed a significant decrease (p<0.05) in the Roxarsone groups and the restrict feeding group, two-week-Roxarsone treatment significantly increased NADP-malic dehydrogenase (MDH) activity compared to the restrict (p<0.05). After 2 weeks drug withdrawal, the 1-week-Roxarsone or restrict feeding group showed significantly increased (p<0.05) glucose-6-phosphate dehydrogenase (G-6-PDH) activity (p<0.05). Two-week-Roxarsone treatment significantly decreased (p<0.05) the high density lipoprotein (HDL) and increased (p<0.05) the low density lipoprotein (LDL) and very low density lipoprotein (VLDL) ratio. After drug withdrawal, the 1-week-Roxarsone or restrict feeding group showed significantly increased (p<0.05) creatine kinase (CK) activity. The 2-week-Roxarsone treatment group showed significantly increased (p<0.05) aspartate aminotransferase (AST) activity. The restrict feeding treatment group showed significantly decreased (p<0.05) total protein (TP) concentration. After drug withdrawal, the related enzyme activities in the blood that reflected the liver function were restored to the normal physiological range, except for the total bilirubin concentration and CK activity in the 1-week-Roxarsone group. This group showed a significant increase (p<0.05). Thus, the reasons for liver enlargement in the Roxarsone and restrict feeding groups were different.
Highlights
Roxarsone (3-nitro-4-hydroxyphenylarsonic acid) is a pentavalent organic arsenical that has been used as feed additive for a half century
Roxarsone has been widely accepted as a feed additive in combination with antibiotics in broiler diets in the US (Waldroup et al, 1995) as well as in the other parts of the world
Roxarsone has been banned from use as feed additive in the UK and the European Union for more than a decade
Summary
Roxarsone (3-nitro-4-hydroxyphenylarsonic acid) is a pentavalent organic arsenical that has been used as feed additive for a half century. The inclusion of Roxarsone 22.5 to 50 mg/kg showed inconsistent results in broiler diets. Does improve production and Eimeria tenella or E. bruneti infection resistance (McDougald et al., 1992). Roxarsone has been widely accepted as a feed additive in combination with antibiotics in broiler diets in the US (Waldroup et al, 1995) as well as in the other parts of the world. Roxarsone has been banned from use as feed additive in the UK and the European Union for more than a decade. Dietary inclusion of 312 mg/kg Roxarsone for 3 weeks with one-week withdrawal induced fatty livers in laying hens (Chiou et al, 1997).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
